Schedule 13G ownership disclosure
BROOKLYN IMMUNOTHERAPEUTICS
Security class unavailable · CUSIP: 114082100
Event date: 2023-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 9.9900%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-24-020217
- Form type
- SC 13G
- Filer
- Ernexa Therapeutics Inc.
- CIK
- CIK 748592
- Filed
- Jan 31, 2024
- Reporting period
- Dec 31, 2023
- Description
- Schedule 13G beneficial ownership